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Background: Natural orifice transluminal endoscopic surgery (NOTES) is the consequence of further development
of minimally invasive surgery to reduce abdominal incisions and surgical trauma. The potential benefits are
expected to be less postoperative pain, faster convalescence, and reduced risk for incisional hernias and wound
infections compared to conventional methods. Recent clinical studies have demonstrated the feasibility and safety
of transvaginal NOTES, and transvaginal access is currently the most frequent clinically applied route for NOTES
procedures. However, despite increasing clinical application, no firm clinical evidence is available for objective
assessment of the potential benefits and risks of transvaginal NOTES compared to the current surgical standard.
Methods: The TRANSVERSAL trial is designed as a randomized controlled trial to compare transvaginal hybrid
NOTES and laparoscopic-assisted sigmoid resection. Female patients referred to elective sigmoid resection due to
complicated or reoccurring diverticulitis of the sigmoid colon are considered eligible. The primary endpoint will be
pain intensity during mobilization 24 hours postoperatively as measured by the blinded patient and blinded assessor
on a visual analogue scale (VAS). Secondary outcomes include daily pain intensity and analgesic use, patient mobility,
intraoperative complications, morbidity, length of stay, quality of life, and sexual function. Follow-up visits are scheduled
3, 12, and 36 months after surgery. A total sample size of 58 patients was determined for the analysis of the primary
endpoint. The confirmatory analysis will be performed based on the intention-to-treat (ITT) principle.
Discussion: The TRANSVERSAL trial is the first study to compare transvaginal hybrid NOTES and conventionally assisted
laparoscopic surgery for colonic resection in a randomized controlled setting. The results of the TRANSVERSAL trial will
allow objective assessment of the potential benefits and risks of NOTES compared to the current surgical standard for
sigmoid resection.
Trial registration: The trial protocol was registered in the German Clinical Trials Register (DRKS00005995) on
March 27, 2014.
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Figure 1 Trial scheme.
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Rationale
Since natural orifice transluminal endoscopic surgery
(NOTES) was described by Kalloo et al. it has gained the at-
tention of surgeons and gastroenterologists worldwide [1].
Aiming to further minimize surgical trauma by reducing
transabdominal incisions, NOTES may be seen as an attempt
to further develop minimally invasive surgery. The potential
benefits of avoiding abdominal incisions with NOTES are less
postoperative pain, faster convalescence, and reduced risk of
incisional hernias and wound infections. However, these po-
tential advantages have not yet been proven conclusively.
Several NOTES concepts are currently in development.
Though pure NOTES is performed exclusively via translu-
minal access, hybrid NOTES combines transluminal access
with conventional laparoscopic access. Pure NOTES proce-
dures are technically challenging and have been applied
only in sporadic clinical cases [2-4]. In contrast, hybrid
NOTES procedures allow the use of rigid instruments and
are technically very similar to conventional laparoscopic
procedures. Surgical access can be created and closed
under laparoscopic view using a transabdominally placed
trocar and the specimen removed via transluminal access.
Due to these benefits, hybrid NOTES procedures have ad-
vanced to clinical application [5-9].
Based on gynecological experience, transvaginal access
was the first transluminal access and advanced to the
most frequently applied route for NOTES [7]. Several
studies have confirmed the feasibility and safety of trans-
vaginal cholecystectomy [5,6,8] and colonic resection
[10,11] using the hybrid NOTES approach.
NOTES is still met with broad skepticism because its po-
tential benefits are generally doubted and potential access-
related complications feared. However, despite increasing
clinical application, there is no firm evidence for objective
assessment of the potential benefits and risks of NOTES.
In particular, no study has compared transvaginal hybrid
NOTES sigmoid resection and conventional laparo-
scopic surgery in a randomized controlled setting.
Objective
The TRANSVERSAL (‘Transvaginal hybrid NOTES versus
conventionally assisted laparoscopic sigmoid resection for
diverticular disease’) trial is a randomized controlled trial
intended to evaluate transvaginal hybrid NOTES and con-
ventionally assisted laparoscopic sigmoid resection. The
study design allows objective assessment of the potential
benefits and risks of transvaginal NOTES compared to the
current laparoscopic standard for sigmoid resection.
Methods/Design
Trial design
The TRANSVERSAL trial is a randomized controlled
multicenter trial comparing transvaginal hybrid NOTESsigmoid resection (experimental intervention) to conven-
tionally assisted laparoscopic sigmoid resection (control
intervention) and is designed as a parallel group superior-
ity trial. The trial scheme is illustrated in Figure 1.
Study population and eligibility criteria
All female patients aged ≥18 years and referred to elect-
ive sigmoid resection due to diverticulitis of the sigmoid
colon will be screened for inclusion (Table 1). Patient
screening comprises an investigation of the patient’s
medical history and findings, a physical examination,
and a routine gynecological examination performed by a
gynecologist in all cases.
Trial locations
The TRANSVERSAL trial will be conducted at three
centers with expertise in transvaginal hybrid NOTES:
 Department of General, Abdominal, and
Transplantation Surgery, University of Heidelberg,
Heidelberg, Germany
 Department of Surgery, Kantonsspital Baselland,
Bruderholz, Switzerland
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Female patients indicated for elective
sigmoid resection due to at least two
episodes of uncomplicated diverticulitis
or first episode of complicated
diverticulitis classified as IIa or IIb
according to Hansen and Stock [12]
• ASA classification higher
than III
• Age ≥18 years • Inability to consent
• Informed consent • Pregnancy
• Genital infections
• Neoplasms of vulva, vagina,
or cervix
• Douglas endometriosis
• History of pelvic floor repair




• Regular use of analgesics,
steroids, or antidepressants
ASA, American Society of Anesthesiologists.
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Sinsheim, GermanyOrganizational structure and responsibilities
The principal investigator (B.M.) is primarily responsible
for the preparation of the study protocol and the case
report form (CRF), the organization of steering commit-
tee meetings, and the dissemination policy. At each par-
ticipating center, a lead investigator (G.L., A.Z., T.S.) is
responsible for screening, recruitment, data collection,
and completion of the CRFs. All lead investigators are
members of the study steering committee, which over-
sees study progress and safety. Prior to creation of the
study protocol, standardization of the intervention, peri-
operative management, patient recruitment, and study
visits was homogenized during steering committee meet-
ings. Further meetings are intended to occur before en-
rollment of the first patient. Surgery will be performed
by the principal investigator and the lead investigators
with an experience of >50 laparoscopic colorectal resec-
tions and >20 transvaginal hybrid NOTES procedures.
Further meetings are intended to occur before enrollment
of the first patient. Patient enrollment, randomization, and
data management will be carried out by the Study Center
of the German Surgical Society (SDGC) at the University
of Heidelberg.Sample size
A total of 58 patients will be randomized for this trial,
29 patients per group.Recruitment and trial timeline
Female patients aged ≥18 years presenting for elective
sigmoid resection due to at least two episodes of uncom-
plicated diverticulitis or the first episode of complicated
diverticulitis classified as IIa or IIb according to Hansen
and Stock [12] will be further screened for eligibility cri-
teria by surgical consultants at the participating centers.
Surgical consultants from all centers will be informed
about the TRANSVERSAL trial and its inclusion criteria
during department meetings. For informed consent, the
patients will be verbally introduced to the trial by a
member of the research group and in writing via the
Patient Information Sheet (Additional files 1, 2, 3 and
4). Informed consent will be obtained from each pa-
tient before inclusion in the study.
Before inclusion in the study, the feasibility of both
techniques will be confirmed by diagnostic laparoscopy
to avoid inclusion of patients who are immediately con-
verted to open surgery. Potential reasons for conversion
to open surgery are pronounced adhesions or tissue
scarification due to prior surgery or prior episodes of
diverticulitis. However, the decision is subject to the
assessment of the respective surgeon. Therefore, the
reasons for technical infeasibility and other reasons for
exclusion will be recorded anonymously alongside de-
scriptive data for all screened patients and presented
in the final study report. If experimental or control in-
terventions seem technically feasible to the surgeon
during diagnostic laparoscopy, patients will be enrolled
at the participating centers. A total of 100to 150 female
patients are expected to be referred for elective surgery
for diverticulitis. Based on the experiences in our previous
study, we expect a recruitment rate of 60 to 70% [11].
Recruitment strategies, such as provisions or financial
compensation, are not intended. The recruitment of 58
patients is planned to be finished within 24 months.
The time interval from first patient in to last patient
out will be 60 months.
Randomization, allocation concealment, and blinding
The SDGC will enroll and randomize patients immediately
after diagnostic laparoscopy and confirmation of the tech-
nical feasibility of both procedures by the surgeon. The pa-
tients will be randomized using an online randomization
tool (http://www.randomizer.at). Randomization will be
stratified by computer-generated permuted blocks of vary-
ing size with a 1:1 ratio to the experimental and control
intervention groups. Patient allocation will be revealed to
the surgeon after randomization by a study nurse using a
written form, which will be destroyed immediately after
unveiling. A standardized wound dressing will be applied
after both techniques to cover the trocar and minilaparot-
omy sites (Figures 2 and 3). Investigators and patients will
be blinded to the group affiliation until removal of the
Figure 2 Trocar positions and standardized wound dressing for the experimental intervention. *transvaginal trocar.
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formed by investigators who are not involved in the surgi-
cal procedures. The wound dressing will be changed with
the patient blinded using blinding glasses on postoperative
day (POD) 2 and at 3-day intervals thereafter. At each cen-
ter, a study nurse will be in charge of changing the wound
dressing and will not be involved further in the trial. If un-
scheduled wound dressing is necessary, the indication and
time point will be documented. In the case of wound com-
plications, patients and investigators will be unblinded.
The surgical report and all patient files will be blinded for
surgical technique. To evaluate the success of the blinding
procedure, the patient's and investigator's suspicion of
group affiliation will be documented before measuring the
primary endpoint and before regular unblinding at dis-
charge. In the case of adverse events, unblinding may be
performed prematurely based on the assessment of the
principal investigator. The patients' allocated interventions
can be revealed at any time by accessing the allocation list
within the trials office.
Interventions
Experimental intervention
Transvaginal hybrid NOTES sigmoid resection will be
performed in the lithotomy position. A 5-mm trocar will
be placed umbilically via an incision and a 12-mmHgcarbon dioxide pneumoperitoneum established. Three
additional 5-mm trocars will be placed under laparo-
scopic view: one suprapubically, one in the right lower
quadrant, and one in the left lower quadrant (Figure 2).
Before every skin incision, a local anesthetic (3 mL of
bupivacaine 0.25%) will be applied subcutaneously. After
laparoscopic exploration of the abdomen, standard medial-
to-lateral mobilization of the sigmoid colon will be per-
formed. For introduction of the stapler device, a 12-mm
transvaginal trocar will be inserted through the posterior
fornix after antiseptic wash-out of the vagina. After distal
dissection of the sigmoid colon, a dorsal colpotomy will be
performed and the colon carefully externalized through a
transvaginal wound protector. Proximal dissection of the
sigmoid colon will be performed extracorporally using an
energy device. A purse-string suture will be placed at the
proximal end of the colon and the circular stapling anvil
inserted into the colon. After intra-abdominal relocation of
the descending colon, the colpotomy will be sutured trans-
vaginally with resorbable thread. An end-to-end anasto-
mosis will be performed under laparoscopic view using
a circular stapling device. Air-leak testing will be per-
formed routinely by transanal insufflation of air with
the anastomosis immersed in saline solution. After su-
turing the fascia and cutis, the standardized wound
dressing will be placed.
Figure 3 Trocar positions and standardized wound dressing for the control intervention. †a 5 mm trocar incision will be extended to
Pfannenstiel minilaparotomy.
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Conventionally assisted laparoscopic sigmoid resection
will be performed in the lithotomy position. A 5-mm
umbilical trocar will be inserted via an incision. After es-
tablishing a 12-mmHg carbon dioxide pneumoperito-
neum, three additional transabdominal trocars will be
placed under laparoscopic view: one 12-mm trocar in
the right lower quadrant, one 5-mm trocar in the left
lower quadrant, and one 5-mm trocar at the suprapubic
midline (Figure 3). Before every skin incision, local
anesthetic (3 mL of bupivacaine 0.25%) will be applied
subcutaneously. After medial-to-lateral mobilization of
the descending colon, a laparoscopic stapling device will
be used to dissect the distal end of the sigmoid colon.
Pfannenstiel minilaparotomy will be performed to ex-
tract the sigmoid colon, extending the incision for the
trocar placed within the suprapubic midline. After extra-
corporeal dissection of the proximal end, the anvil for
the circular stapling device will be placed within the
colon and secured with a purse-string suture. For colo-
rectal anastomosis, the colon will be reintroduced intothe peritoneal cavity. An end-to-end stapler anastomosis
and air-leak test will be performed as described above.
After suturing the fascia and cutis, the standardized
wound dressing will be placed.
Perioperative management, discharge, and follow-up
Perioperative thrombosis prophylaxis will be performed
according to current German guidelines [13]. Single-
shot antibiotics (ampicillin/sulbactam) will be given 30
minutes before surgery. Intraoperative anesthesia will com-
prise intravenous administration of piritramide. Postopera-
tively, pain medication will be administered according to
the World Health Organization (WHO) analgesic ladder
based on the judgment of the treating ward physician be-
ginning directly after surgery in the recovery room [14].
Nonsteroidal anti-inflammatory drugs (metamizol) will be
administered solely or in combination with a weak (tilidine)
or strong opioid (piritramide, oxycodone). Peridural anal-
gesia is not part of the pain management in this study. On
the day of surgery and POD 1, analgesics will be adminis-
tered intravenously. Beginning from POD 2, analgesics will
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blood samples are scheduled for POD 1 to 5. Patients will
be encouraged for discharge from POD 5 onward upon
complete fulfillment of the discharge criteria (see ‘Dis-
charge criteria’). Patients who receive the experimental
intervention will be recommended to attend an ambula-
tory gynecological checkup 10 days after surgery. All pa-
tients will be followed up at an ambulatory checkup
scheduled 3, 12, and 36 months after surgery. The ambu-
latory checkup will comprise taking a history, a clinical
examination, and an assessment of secondary endpoints.
Patients will be notified in writing and by phone in case
they fail to return for their follow-up visits. If reaching the
patients directly is not possible, their general practitioner
will be contacted. Missing follow-up data will then be
completed by phone.
Discharge criteria
Patients will be discharged upon complete fulfillment of
the following criteria:
 ≥POD 5
 Full oral intake
 ≥1 passage of stool
 Regular primary wound healing
 Adequate pain control (VAS ≤3 under mobilization)
with NSAID and low-potent opioid (tilidine)
 In-ear body temperature ≤38°C
 Decreasing laboratory markers of inflammation
(CRP, leukocytes)
CRP, C-reactive protein; NSAID, nonsteroidal
anti-inflammatory drug; POD, postoperative day;
VAS, visual analogue scale.Risk-benefit ratio
The potential benefits of transvaginal hybrid NOTES
sigmoid resection are expected to be less postoperative
pain, faster convalescence, and reduced risk of wound
infections and incisional hernia compared to conven-
tional methods. The potential complications related to
NOTES access are disturbed vaginal wound healing, im-
paired sexual function, and transvaginal microbiological
contamination of the peritoneal cavity. In a recent study,
we found a positive bacterial culture in the Douglas pouch
following colpotomy in 2 of 27 (7%) patients undergoing
transvaginal cholecystectomy. However, in both cases
peritoneal contamination did not impact morbidity [15].
Two studies assessed postoperative sexual function after
transvaginal NOTES cholecystectomy and did not find
impairment after a follow-up of 12 months [16,17]. In a
cohort study of 44 patients undergoing transvaginal hybrid
NOTES sigmoid resection we found major complications
(≥grade 3) in 2 patients (4.4%) and minor complications
(<grade 3) in 10 patients (22.2%) [11]. No mortalityoccurred [11]. Overall, these rates are comparable to
previously published literature on assisted laparoscopic
sigmoid resection for diverticular disease [18,19]. Con-
sequently, no evidence yet indicates higher morbidity
after transvaginal hybrid NOTES sigmoid resection
compared to the assisted laparoscopic approach.
Outcome parameters
Primary endpoint
The primary endpoint is intensity of pain measured by a
visual analogue scale (VAS) during mobilization of the
patient 24 hours postoperatively. Patients and investigators
will be blinded for this measurement. Before mobilization
of the patient, the investigator will provide a standardized
explanation of the VAS using a written text. The patient
will be asked to record current pain intensity by drawing a
vertical line on a horizontally positioned 100-mm VAS ran-
ging from 0 (no pain) to 10 (worst imaginable pain). For
mobilization, patients will be asked to take a seated pos-
ition at the edge of the bed, to stand up, and finally to lie
down in bed again. Immediately after mobilization, the pa-
tient will be asked to record the maximum pain intensity
experienced during mobilization.
Secondary endpoints
Secondary endpoints will be measured intraoperatively,
at daily study visits, and 3, 12, and 36 months postopera-
tively. Intraoperative parameters comprise operation
time, length of minilaparotomy, height of the anasto-
mosis and the length of the unfixed specimen. The number
of harvested lymph nodes will be determined postopera-
tively by pathological examination. The schedule for study
visits and follow-up is provided in Table 2. Pain intensity
will be measured at rest and during mobilization in the
same way as the primary endpoint. The dose and identity
of applied analgesics will be recorded daily. Daily analgesic
use will be graded using a numeric scale from one to three
according to the WHO analgesic ladder [14]. Cumulative
analgesic use will be assessed by adding daily WHO anal-
gesic ladder scores. Daily patient mobility will be measured
in meters by an electronic pedometer device, which will be
placed on the wrist of the nondominant hand of the pa-
tient. Cumulative patient mobility will be assessed by
adding daily distances. Inflammatory parameters (leu-
kocytes, C-reactive protein) will be measured daily
from POD 1 to POD 5. The discharge criteria (See
‘Discharge criteria’) will be evaluated beginning from
POD 5. After discharge, the patients will be asked to
record daily analgesic use and activity on a scale ran-
ging from 0 (inactivity) to 5 (return to usual activities)
until they return to usual activities and stop pain medi-
cation on a standardized form, which will be evaluated
at the 3-month follow-up visit. Morbidity according to
Dindo et al. [20] will be assessed at discharge, 3, 12,
Table 2 Postoperative outcome parameters and schedule of study visits and follow-up
Outcome parameter Daily in-hospital study visits Follow-up
POD 1 (24h)* POD 2 to POD 5 ≥ POD6 Discharge 3 months 12 months 36 months
Pain intensity (VAS) X (primary outcome) X X X
Daily analgesic use X X
Cumulative analgesic use X (POD 5)† X X
Daily patient mobility X X X
Cumulative patient mobility X
Inflammatory parameters (CRP, leukocytes) X X
Discharge criteria X (POD5)† X
Length of stay X
Morbidity X X X X
Return to normal activities X
Quality of life (GIQLI [21]) X X X
Sexual function (FSFI [22]) X X X
Cosmetic satisfaction (Body Image Scale [23]) X X X
*Study visit on POD 1 is scheduled 24 hours postoperatively; †parameters will be measured solely on POD 5. CRP, C-reactive protein; FSFI, Female Sexual Function
Index; GIQLI, Gastrointestinal Quality Of Life Index; POD, postoperative day; VAS, visual analogue scale.
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reported outcomes will be assessed preoperatively and
3, 12, and 36 months postoperatively: quality of life
measured by the Gastrointestinal Quality of Life Index
(GIQLI) [21], sexual function measured by the Female
Sexual Function Index (FSFI) [22], and cosmetic satis-
faction measured by the Body Image Scale [23].
Data management
Data will be entered in a CRF by the investigator or a
designated representative of the respective center. Par-
ticipant names and collected data are subject to medical
confidentiality. In the case of resignation, collected data
may be pseudonymized unless the participant explicitly
requests that all data be erased. Data will be entered into
the CRF as soon as possible after data retrieval. After
completion, the original CRF will be sent to the SDGC
for validation and transfer into the trial database. Double
data entry will be performed in order to ensure accurate
transfer from the CRF to the database. At the end of the
trial, the original CRFs and final database will be ar-
chived by the principal investigator, who is responsible
for providing data to trial investigators. All trial mem-
bers are obliged to ensure the deletion of duplicate data
recordings at the end of the trial.
Safety and reporting of serious adverse events
Serious adverse events (SAEs), defined according to the
guidelines for good clinical practice by the International
Conference on Harmonization of Technical Require-
ments for Registration of Pharmaceuticals for Human
Use (ICH-GCP), will be reported from the day of first
enrollment until the regular end of the trial [24]. AllSAEs will be documented in a separate ‘serious adverse
event form’ and the CRF, and will be reported to the
principal investigator within 24 hours of being noted. If
the principal investigator considers a SAE as unexpected
and related to the study intervention, he will submit a
report to the local ethics committee within 3 days. Fur-
thermore, morbidity will be documented within the
CRF. The study steering committee will meet to evaluate
morbidity and SAEs at least twice: after randomization
of one-third of the patients and after randomization of
two-thirds of the patients. In the case of relevant imbal-
ances between the groups, a report will be submitted to
the local ethics committee. The trial may be terminated
based on the decision of the principal investigator ac-
cording to the assessment of the local ethics committee.
Statistical methods
Sample size
Sample size was determined for the primary endpoint,
the intensity of pain during mobilization measured on
the VAS 24 hours after surgery. Park et al. reported a
mean (± standard deviation) VAS score of 4.2 ± 1.7
for transvaginal hybrid NOTES vs. 5.7 ± 1.7 for con-
ventional laparoscopic right-sided hemicolectomy [10].
According to Gallagher et al. a standardized effect size
of unity in the VAS score (difference in unity given a
standard deviation of unity) is discriminable by pa-
tients and can be considered clinically relevant [25].
We made the following assumptions when calculating
the patient number:
 Hypothesis: transvaginal hybrid NOTES sigmoid
resection causes less pain than laparoscopic-assisted
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analysis).
 Two-sided analysis with a type I error (α) of 0.05
and power (1-β) of 0.90. The standardized effect size
was assumed to be 1 (difference in VAS of 1 and
standard deviation of 1). The power was set at 0.90
because some evidence is already available.
Based on these assumptions, a sample size of 23 patients
per arm was calculated using the R package (version 0.1-8;
http://cran.r-project.org/web/packages/Sample.Size/index.
html, t test for two independent samples). Assuming a
drop-out rate of 20%, the total number of patients needed
per arm is 29, resulting in a total patient number of 58
patients for the primary arm.Statistical analysis
Statistical analysis will be performed using the R statis-
tical software (http://www.r-project.org). A two-sided
P value <0.05 will be considered significant. For base-
line characteristics, descriptive statistics will be used.
For analysis of the primary outcome, a Mann-Whitney
U test will be applied. For categorical secondary end-
points, chi-square statistics will be used. To compare
continuous secondary endpoints (operating time, length
of hospital stay, analgesic use, time to return to normal ac-
tivity), Mann-Whitney U tests will be applied. No interim
analysis is planned for this study. For the time course of
pain at provocation and at rest, a mixed model with mean
VAS scores will be applied.
Missing values will be replaced with the last available
value (the last observation carried forward (LOCF) ap-
proach). Data from patients who withdraw from the
study will be disregarded unless exclusion is based on
postoperative patient wishes and the patient agrees to
the use of the already obtained data.
The confirmatory analysis will be performed based on
intention-to-treat (ITT) patients and with respect to
ITT principles. A standard sensitivity analysis will be
performed on the per-protocol population.Ethical approval
The ethics committee of the University of Heidelberg
reviewed and approved this study on January 13, 2014
(reference number: S-608/2013).Good clinical practice
The trial was conceived and will be conducted ac-
cording to all relevant national and international rules
and regulations, such as the guidelines for good clin-
ical practice by the ICH-GCP [24] and Declaration of
Helsinki (2013) [26].Dissemination policy
The results of the TRANSVERSAL trial are intended to
be presented at international medical congresses on cor-
responding fields of interest, for example, general and
visceral surgery or endoscopic surgery. Written publica-
tions are planned within surgical or endoscopic scientific
journals. The authorship for written publications has to
be confirmed unequivocally by all lead investigators and
will only be granted in the case of substantive contri-
butions to the design, conduct, data analysis, and inter-
pretation. The contact data for all lead investigators and
access to the full study protocol will be presented online
on the website of the surgical department of the University
of Heidelberg (http://www.klinikum.uni-heidelberg.de/
Chirurgische-Klinik.1010.0.html). After completion of
the full study report, anonymized participant-level data-
sets and the statistical code for generating results will be
available by contacting the principal investigator.
Registration
The study protocol has been registered with the German
Clinical Trials Register (https://drks-neu.uniklinik-
freiburg.de/drks_web/) under the registration number
DRKS00005995.
Protocol version
This manuscript refers to the fourth version of the full
study protocol issued on August 26, 2014. Protocol modi-
fications will be reported to all investigators, the local eth-
ics committee, the German Clinical Trials Register, all trial
participants, and the journal.
Discussion
NOTES represents a consequence of developing minim-
ally invasive surgery to reduce abdominal wall trauma
using natural orifice access to the peritoneal cavity.
Laparoscopic-assisted surgery may eventually advance to
pure laparoscopic surgery, as minilaparotomy can be
avoided by using the natural orifice for specimen re-
trieval. Since the white paper in which members of the
Society of American Gastrointestinal and Endoscopic
Surgeons (SAGES) and American Society for Gastro-
intestinal Endoscopy (ASGE) presented future require-
ments for the development and clinical application of
NOTES, clinical and experimental studies have focused
on feasibility [27]. Although transvaginal NOTES proce-
dures have already entered the clinical routine, only a
few studies have compared NOTES to current standard
surgical treatment [10,28,29].
Pain intensity 24 hours after surgery has been chosen as
a primary endpoint of TRANSVERSAL trial because pain
is one of multiple outcomes reflecting trauma and recov-
ery after abdominal surgery [30]. In contrast to other fac-
tors, pain may be objectified well using the VAS, a test
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iety of physiological processes, such as the stress response,
inflammation, and wound healing, we think that pain may
represent a decisive factor within the recovery process.
We decided to measure pain intensity during mobilization
of the patient because, even under closely monitored anal-
gesic treatment, pain may be provoked by mobilization
and affect postoperative patient mobility. The secondary
endpoints of the TRANSVERSAL trial comprise add-
itional outcomes reflecting recovery, such as postoperative
patient mobility measured by an electronic pedometer,
quality of life, length of hospital stay, and time to return
to normal activity.
To the best of our knowledge only three randomized con-
trolled trials have compared transvaginal hybrid NOTES to
laparoscopic surgery, and all of the studies assessed the
transvaginal NOTES technique applied to cholecystectomy
[28,29,32]. In 60 female patients, Noguera et al. found no
differences with regard to morbidity, postoperative pain,
length of stay, and time off work for hybrid transvaginal
NOTES, hybrid transumbilical NOTES, and conven-
tional laparoscopic cholecystectomy at 1-year follow-
up. In contrast, in a recent randomized controlled trial
including 40 female patients, Bulian et al. found that
the transvaginal hybrid NOTES technique is associated
with less postoperative pain, less analgesic use, and im-
proved postoperative quality of life compared to nee-
dlescopic three-trocar cholecystectomy in the short term
(POD 1 to POD 10). Borchert et al. found no significant
difference between transvaginal hybrid NOTES and
laparoscopic cholecystectomy with regard to postoper-
ative pain and safety in 97 patients in the short term
(POD 1 to POD 7).
With regard to colorectal surgery, clinical evidence for
NOTES procedures is limited to cohort studies and one
matched controlled study. Cohort studies have shown
the feasibility of transvaginal and transanal specimen ex-
traction for colonic resection [11,33-35]. In a matched
cohort study including 68 patients, Park et al. found that
transvaginal specimen extraction for right-sided hemico-
lectomy is associated with less pain and shorter hospital
stay than the laparoscopic-assisted technique. No differ-
ence was found with regard to morbidity after a median
follow-up of 23 months [10].
Despite increasing clinical application, NOTES has still
encountered broad skepticism because its potential ben-
efits are generally doubted and potential access-related
complications feared. The TRANSVERSAL trial is the
first study comparing NOTES to conventionally assisted
surgery for colonic resection in a randomized controlled
setting. The results of this trial will provide valuable
clinical evidence for objective assessment of the poten-
tial benefits and risks of NOTES procedures compared
to the current surgical standard.Trial status
Recruitment will begin in the fourth quarter of 2014.
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